Core Insights - Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies through PLK1 inhibition [3] - The company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, with a live webcast available for interested parties [1][2] Company Overview - Cardiff Oncology is advancing innovative cancer treatments, particularly targeting PLK1 inhibition, which is recognized as a validated oncology target with significant potential to change clinical practice [3] - The lead asset, onvansertib, is an oral PLK1 inhibitor currently in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large patient population with high unmet needs [3] - Onvansertib is also being investigated in other PLK1-driven cancers through ongoing investigator-initiated trials and has demonstrated robust clinical activity as a single agent in challenging tumors [3]

Core Viewpoint - Cardiff Oncology Inc. experienced a significant decline of approximately 32% in stock price following management and trial updates, indicating investor concern over leadership changes and clinical trial focus [1][9]. Management Changes - Mani Mohindru has been appointed as interim CEO, effective immediately, following the resignation of CEO Mark Erlander and CFO James Levine [1][2]. - Brigitte Lindsay has been promoted to Chief Accounting Officer to ensure financial continuity, having been with the company for over 14 years [2]. Clinical Trial Update - Cardiff Oncology provided an update on the CRDF-004 trial, which is a Phase 2 study evaluating onvansertib in combination with standard care regimens for patients with RAS-mutated metastatic colorectal cancer [3]. - The trial showed a 72.2% confirmed objective response rate in the 30 mg dose group of onvansertib with FOLFIRI/bevacizumab, compared to 43.2% in the standard care group, approaching statistical significance (p-value = 0.051) [4]. - Progression-free survival was statistically significant for the 30 mg onvansertib plus FOLFIRI/bevacizumab group (p-value = 0.048), with median progression-free survival not yet reached in the treatment groups [5]. Future Plans - Based on the trial results, the company plans to advance the 30 mg dose of onvansertib with FOLFIRI/bevacizumab into a registrational trial for first-line patients with RAS-mutated metastatic colorectal cancer, pending FDA consultation [6]. - The focus will be narrowed to onvansertib in combination with FOLFIRI, which may reduce the total addressable market in the frontline setting to 12%-20% from a previous estimate of 40%-50% [8]. Analyst Commentary - Analysts from William Blair expressed concerns regarding the abrupt management changes and the narrowed focus on onvansertib with FOLFIRI, leading to a reduction in the probability of success from 50% to 45% [8]. - Despite the concerns, William Blair maintains an Outperform rating for the stock [9].

Summary of Cardiff Oncology Update Call Company Overview - **Company**: Cardiff Oncology (NasdaqCM:CRDF) - **Focus**: Development of onvansertib, a highly specific oral PLK1 inhibitor, primarily for RAS-mutated metastatic colorectal cancer (mCRC) patients Key Points Management Transition - Cardiff Oncology announced a management transition to better position the company for late-stage development of onvansertib [5][6] - Mani Mohindru appointed as Interim CEO, emphasizing the need for leadership aligned with the company's evolving operational and financial needs [4][5] Clinical Trial Updates - Promising phase 2 data from the CRDF-004 trial for onvansertib in first-line RAS-mutated mCRC patients was discussed [5][7] - The trial evaluated onvansertib in combination with standard care regimens (FOLFIRI plus bevacizumab or FOLFOX plus bevacizumab) [8] - Dose-dependent benefits observed, particularly with the 30 mg dose of onvansertib combined with FOLFIRI plus bevacizumab, showing an overall objective response rate of 72.2% compared to 43.2% with FOLFOX and 42.1% with FOLFIRI alone [10][11] Efficacy and Safety Data - Median progression-free survival (PFS) has not yet been reached in the onvansertib arms, indicating extended benefit compared to a median PFS of about 11 months for standard care [10] - The PFS hazard ratio was reported at 0.37 for the 30 mg onvansertib plus FOLFIRI bev arm, indicating a significant reduction in disease progression risk [11] - Safety profile remains favorable, with no unexpected toxicities reported; grade 3 or higher adverse events were infrequent [12] Future Plans - Cardiff plans to initiate a registrational study later in 2026, comparing onvansertib plus FOLFIRI to standard care regimens [12][14] - The study protocol will likely include both FOLFIRI and FOLFOX in the control arm to provide comprehensive data for regulatory review [13] - Anticipation of more mature clinical data from the CRDF-004 study by mid-2026 [14] Strategic Considerations - Discussions regarding potential partnerships to support the phase 3 trial and broaden development beyond initial indications are ongoing [33] - The company is focused on building a leadership team with experience in late-stage development and commercialization [76] Additional Insights - The transition in leadership is not due to issues with onvansertib but rather a strategic move to capitalize on promising data [6] - The focus on durability of response is emphasized, with stable disease being a significant factor in treatment efficacy [24][25] - The company is committed to maintaining operational continuity during the management transition [7] Conclusion Cardiff Oncology is positioned for significant growth with onvansertib, supported by promising clinical data and a strategic management transition aimed at enhancing its late-stage development efforts. The upcoming registrational study and potential partnerships are critical steps in advancing the drug's market potential.

Core Insights - Cardiff Oncology, Inc. announced positive results from the CRDF-004 Phase 2 clinical trial, demonstrating that onvansertib combined with FOLFIRI/bevacizumab (bev) shows dose-dependent improvements in overall response rates and progression-free survival (PFS) in patients with RAS-mutated metastatic colorectal cancer (mCRC) [1][3][4] Group 1: Clinical Trial Results - The trial showed that the 30 mg dose of onvansertib with FOLFIRI/bev is selected for further registrational trials based on its efficacy [2][3] - In the intent-to-treat analysis, onvansertib with FOLFIRI/bev outperformed both standard of care (SoC) regimens, with a confirmed objective response rate (ORR) of 44.4% for the 30 mg dose [1][3] - Median PFS for the 30 mg onvansertib group was not reached, indicating a potential benefit over SoC [3][4] Group 2: Safety and Tolerability - Onvansertib was reported to be safe and well-tolerated, with no significant additive toxicity observed in the trial [1][3] - Grade 3 or higher adverse events were infrequent, with neutropenia being the most common treatment-emergent adverse event [5] Group 3: Future Plans - Cardiff Oncology plans to initiate a registrational program later this year, pending finalization of trial design in consultation with the FDA [2][3] - The company expects to provide final data and registrational plans in the first half of 2026 [1][3] Group 4: Industry Context - There is a significant unmet need for improved first-line treatment options for patients with RAS-mutated mCRC, as current treatments have not significantly advanced in over two decades [5] - Onvansertib's novel mechanism of action and promising preliminary results support the need for further investigation in a large Phase 3 trial [5]

Core Insights - Cardiff Oncology, Inc. is undergoing a leadership transition to support its growth and advancement towards late-stage development and key clinical milestones [1][4] - Mani Mohindru, PhD, has been appointed as interim Chief Executive Officer, following the departure of Mark Erlander, PhD, and James Levine [2] - The company is actively searching for a permanent Chief Executive Officer and Chief Financial Officer [3] Leadership Changes - Mani Mohindru has been a member of Cardiff Oncology's Board of Directors since 2021 and has extensive experience in the biotech sector [2][6] - Brigitte Lindsay has been promoted to Chief Accounting Officer, ensuring continuity in the finance function [3] - The leadership transition is aimed at aligning executive and financial leadership with the company's evolving needs [5] Product Development - Cardiff Oncology's lead product candidate, onvansertib, is a specific oral PLK1 inhibitor currently in mid-stage clinical development for RAS-mutated metastatic colorectal cancer (mCRC) [4][7] - Onvansertib is also being evaluated in various other cancers, including pancreatic ductal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, and chronic myelomonocytic leukemia [4] - The company aims to leverage onvansertib's activity to extend its benefits to other solid tumors and hematologic malignancies [5] Strategic Focus - The leadership transition reflects the company's commitment to execution and clinical advancement as its programs mature [4] - Dr. Mohindru emphasizes the importance of sharpening strategic priorities and advancing clinical programs while maintaining a disciplined approach to capital and execution [5]

Summary of Cardiff Oncology Conference Call Company Overview - **Company**: Cardiff Oncology (NasdaqCM: CRDF) - **Focus**: Development of onvansertib, a first-in-class PLK1 inhibitor targeting RAS-mutated metastatic colorectal cancer [2][35] Key Points and Arguments Product and Mechanism - **Onvansertib**: A highly selective PLK1 inhibitor designed for first-line treatment of RAS-mutated metastatic colorectal cancer [2][4] - **Mechanism**: PLK1 is an enzyme that drives tumor cell division and survival; onvansertib inhibits this enzyme, leading to reduced tumor growth and metastasis [3][4] Clinical Trials and Efficacy - **Clinical Trials**: Initial trials showed strong efficacy signals in RAS-mutated metastatic colorectal cancer, particularly in BEV-naive patients [3][11] - **Response Rates**: In a second-line trial, onvansertib combined with standard care showed a 73% response rate in BEV-naive patients compared to 16% in BEV-exposed patients [11] - **Progression-Free Survival (PFS)**: Nearly doubled in BEV-naive patients compared to historical controls [11] Market Opportunity - **Unmet Need**: Colorectal cancer has a low five-year survival rate of only 15%, with no new therapies introduced in over 20 years for RAS-mutated patients [5][6] - **Target Population**: Approximately 50% of newly diagnosed colorectal cancer patients have RAS mutations, indicating a significant market opportunity [6][35] Regulatory and Development Path - **FDA Alignment**: Received clear guidance from the FDA to pivot from second-line to first-line clinical development, addressing a larger patient population [4][18] - **Ongoing Trials**: The ongoing first-line trial is designed to assess the efficacy of onvansertib in combination with standard chemotherapy [19][20] Safety and Tolerability - **Safety Profile**: Onvansertib is well tolerated, with no significant increase in neutropenia compared to control groups [30][31] - **Combination Therapy**: The drug can be combined with existing chemotherapies without compromising safety, allowing for longer treatment durations [40][41] Financial and Strategic Partnerships - **Partnership with Pfizer**: Pfizer holds a 3% equity stake in Cardiff Oncology and is involved in trial execution through its Pfizer Ignite program, providing high-quality data without strings attached [33][34] Future Outlook - **Next Steps**: Plans to update on trial progress in Q1 of the following year, with a focus on durability data and potential registrational trials [36] - **Investment Opportunity**: The company is positioned to make a significant impact in the treatment of colorectal cancer, presenting a compelling investment opportunity [42][43] Additional Important Information - **Patents**: Two new patents were issued, extending the intellectual property protection for onvansertib until at least 2043 [17] - **Clinical Data Publication**: Findings have been published in the Journal of Clinical Oncology, highlighting the significance of the research [16] This summary encapsulates the critical insights from the conference call, emphasizing Cardiff Oncology's innovative approach to treating colorectal cancer and the potential for significant market impact.

Core Insights - Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing therapies leveraging PLK1 inhibition for various cancers [4] - Clinical data from a Phase 1 trial of onvansertib in chronic myelomonocytic leukemia (CMML) will be presented at the 67th American Society of Hematology Annual Meeting [1][3] Clinical Trial Results - In a Phase 1 dose escalation trial involving 9 patients, onvansertib as a monotherapy was well-tolerated and showed preliminary efficacy in approximately 40% of patients, with one patient achieving an optimal marrow response at the 9 mg/m dose [2] - The results support onvansertib's activity as a single agent in both hematologic and solid tumors, although the company does not plan to develop onvansertib specifically for CMML [2] Presentation Details - The poster presentation titled "Phase 1 clinical trial assessing the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in Relapsed/Refractory myeloproliferative chronic myelomonocytic leukemia (CMML)" will be delivered by Mrinal Patnaik, MD, MBBS, from Mayo Clinic [3] - The presentation is scheduled for December 8, 2025, from 6:00-8:00 PM EST as part of the Myelodysplastic Syndromes session [3] Company Overview - Cardiff Oncology's lead asset, onvansertib, is being evaluated in combination with standard of care therapies for indications such as RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer [4] - The company's development strategy aims to target tumor vulnerabilities to overcome treatment resistance and provide superior clinical benefits compared to standard therapies [4]

Group 1 - Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel therapies through PLK1 inhibition for various cancers [2] - The company's lead asset, onvansertib, is being evaluated in combination with standard of care therapeutics for indications such as RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer [2] - Cardiff Oncology will present at Sidoti's Year-End Virtual Investor Conference on December 11, 2025, with CEO Mark Erlander as the presenter [1] Group 2 - The company's development strategy aims to target tumor vulnerabilities to overcome treatment resistance and provide superior clinical benefits compared to standard of care alone [2] - Interested parties can register for the live webcast of the conference through the Cardiff Oncology website [1]

Core Insights - Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel therapies through PLK1 inhibition for various cancers [3] - The company will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025, with a presentation by CEO Mark Erlander [1][2] Company Overview - Cardiff Oncology is leveraging PLK1 inhibition, a validated oncology drug target, to create therapies for cancers such as RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer [3] - The lead asset, onvansertib, is being evaluated in combination with standard of care therapeutics to address treatment resistance and enhance clinical benefits [3]

Summary of Cardiff Oncology Conference Call Company Overview - **Company**: Cardiff Oncology (NasdaqCM:CRDF) - **Focus**: Development of onvansertib, a first-in-class PLK1 inhibitor targeting RAS mutated metastatic colorectal cancer [4][5] Industry Context - **Industry**: Biotechnology, specifically cancer therapeutics - **Market Need**: Colorectal cancer has a significant unmet need, with a 15% five-year survival rate and less than 12 months progression-free survival for metastatic cases [6] Key Points and Arguments 1. **Onvansertib Mechanism**: - Onvansertib is a selective PLK1 inhibitor, targeting a critical pathway in tumorigenesis and angiogenesis [4][5] - It is designed to be well-tolerated, addressing past toxicity issues associated with PLK1 inhibitors [5][19] 2. **Clinical Trials**: - The ongoing CARDIF-004 trial involves 110 patients with first-line RAS mutated unresectable colorectal cancer, comparing standard care with two doses of onvansertib [9][10] - Preliminary results show confirmed objective response rates (ORR) of 30% for control, 42% for 20 mg, and 49% for 30 mg doses of onvansertib [10][11] 3. **Response Rates**: - The trial indicates faster responses in the experimental arm, with 46% of patients in the 30 mg group achieving a confirmed response at six months compared to 22% in the control group [11] - Waterfall and spider plots demonstrate significant tumor shrinkage in patients receiving onvansertib [12][13] 4. **Safety Profile**: - Safety data shows no significant increase in grade three or higher adverse events compared to control, reassuring investigators about the drug's tolerability [19][20] 5. **Regulatory Pathway**: - Cardiff Oncology has engaged with the FDA to outline a seamless trial design for accelerated and full approval based on response rates and progression-free survival (PFS) [20][21] 6. **Intellectual Property**: - The company has secured patents extending into 2043, enhancing its competitive position in the colorectal cancer market [25] 7. **Financial Position**: - As of the last quarter, Cardiff Oncology reported $60-61 million in cash, providing a runway for ongoing trials and operations [27] 8. **Partnerships**: - Pfizer has invested $15 million in Cardiff Oncology and is involved in the trial's execution, indicating a strong collaborative relationship [26] Additional Insights - **Market Competition**: The competitive landscape is evolving, with new entrants in the KRAS inhibitor space and other innovative therapies targeting colorectal cancer [34][35] - **Patient Outcomes**: Patients achieving complete responses are being considered for curative surgeries, highlighting the potential effectiveness of onvansertib [15][36] - **Future Data Releases**: The company plans to provide more detailed data in Q1 2026, with expectations of median follow-up times around 12 months [28][29] This summary encapsulates the critical aspects of Cardiff Oncology's conference call, focusing on the company's innovative approach to treating colorectal cancer and its strategic positioning within the biotechnology industry.